Products for Research Use Only

KRAS G13D-IN-2

CAT: 0804-HY-179452Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-179452Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
KRAS G13D-IN-2 (compound 8B) is a potent orally active KRAS G13D inhibitor with IC50 values of 1.95 μM (HCT-116G13D) and 2.16 μM (HCT-15G13D) . KRAS G13D-IN-2 induces G1-phase arrest and mitochondrial membrane depolarization. KRAS G13D-IN-2 induces senescence through CDK6/TWIST1 inhibition. KRAS G13D-IN-2 inhibits tumor growth in murine models. KRAS G13D-IN-2 can be used for KRASG13D-mutant colorectal cancer research[1].
UNSPSC
12352211
Target
CDK; Mitochondrial Metabolism; Ras
Related Pathways
Cell Cycle/DNA Damage; GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease
Field of Research
Cancer
Smiles
O[C@@H]1CC[C@@]2(C)[C@](CC[C@]3(C)[C@]2([H])CC=C4[C@@]3(C)CC[C@]5(C)[C@@]4([H])[C@@H](C)[C@H](C)CC5)([H])[C@@]1(C)NC(N[C@@H](CC(C)C)C(O)=O)=O
Molecular Formula
C36H60N2O4
Molecular Weight
584.87
References & Citations
[1]Qayum A, et al. Synthesis of β-boswellic acid-amino acid conjugates for targeting KRASG13D mutant colon cancer. Eur J Med Chem. 2026 Jan 15;302 (Pt 2) :118336.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK6; K-Ras

Popular Products